0001072613-18-000128.txt : 20180212 0001072613-18-000128.hdr.sgml : 20180212 20180212161716 ACCESSION NUMBER: 0001072613-18-000128 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180212 DATE AS OF CHANGE: 20180212 GROUP MEMBERS: CLARUS VENTURES I MANAGEMENT, L.P. GROUP MEMBERS: CLARUS VENTURES I, LLC GROUP MEMBERS: DENNIS HENNER GROUP MEMBERS: KURT WHEELER GROUP MEMBERS: NICHOLAS GALAKATOS GROUP MEMBERS: NICHOLAS SIMON GROUP MEMBERS: ROBERT LIPTAK SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Oxford Immunotec Global PLC CENTRAL INDEX KEY: 0001586049 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-87926 FILM NUMBER: 18596572 BUSINESS ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ BUSINESS PHONE: 44 01235 442780 MAIL ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Clarus Lifesciences I, L.P. CENTRAL INDEX KEY: 0001431445 IRS NUMBER: 203855540 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1210 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-2200 MAIL ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1210 CITY: CAMBRIDGE STATE: MA ZIP: 02142 SC 13G/A 1 clarus-oxfordsch13g_18164.htm CLARUS LIFESCIENCES I, L.P. OXFORD IMMUNOTEC GLOBAL PLC SCHEDULE 13GA - AMEND. #3
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

______________

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 3)*
 
 

 
 
Oxford Immunotec Global PLC
(Name of Issuer)


Ordinary Shares, £0.001 nominal value per share
(Title of Class of Securities)


G6855A 10 3
(CUSIP Number)
 

December 31, 2017
(Date of Event Which Requires Filing of this Statement)

 
 
 

 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)


*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

 
 
CUSIP No. G6855A 10 3
  13G Page 2 of 6 Pages 
 
 
 
Item 1(a).
Name of Issuer:  Oxford Immunotec Global PLC (the "Issuer").

Item 1(b).
Address of Issuer's Principal Executive Offices:

 94C Innovation Drive, Milton Park, Abingdon OX14 4RZ United Kingdom.

Item2(a).
Name of Persons Filing:  Clarus Lifesciences I, L.P. ("Clarus I"), Clarus Ventures I Management, L.P. ( "Clarus I Management"), Clarus Ventures I, LLC ("Clarus I GPLLC"), Nicholas Galakatos ("Galakatos"), Dennis Henner ("Henner"), Robert Liptak ("Liptak"), Nicholas Simon ("Simon") and Kurt Wheeler ("Wheeler"), (each, a "Reporting Person" and collectively, the "Reporting Persons.")  Clarus I Management is the sole general partner of Clarus I.  Clarus I GPLLC is the sole general partner of Clarus I Management.  Galakatos, Henner, Liptak, Simon and Wheeler, (collectively, the "Managers") are all of the managing directors of Clarus I GPLLC.

Item 2(b). Address of Principal Business Office or, if None, Residence:  The business address of each of the Reporting Persons is 101 Main Street, Suite 1210, Cambridge, MA 02142.

Item 2(c). Citizenship:  Clarus I and Clarus I Management are limited partnerships organized under the laws of the State of Delaware.  Clarus I GPLLC is a limited liability company organized under the laws of the State of Delaware.  Each of Galakatos, Henner, Liptak, Simon and Wheeler is a United States Citizen.

Item 2(d). Title of Class of Securities:  Ordinary Shares, £0.001 nominal value per share ("Ordinary Shares").

Item 2(e). CUSIP Number:   G6855A 10 3.

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.
Ownership.
 
Not applicable.
 
Item 5.
Ownership of Five Percent or Less of a Class.
                
Each Reporting Person has ceased to beneficially own five percent (5%) or more of the Issuer's outstanding Ordinary Shares.
 
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
 
Not applicable.
 
CUSIP No. G6855A 10 3
  13G Page 3 of 6 Pages 

 

Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
 
Not applicable.

Item 8.
Identification and Classification of Members of the Group.
 
Not applicable.

Item 9.
Notice of Dissolution of Group.
 
Not applicable.

Item 10.
Certification.
 
Not applicable.  This Schedule 13G is not filed pursuant to Rule 13d‑1(b) or Rule 13d–1(c).

 
Material to be Filed as Exhibits.
 
Exhibit 1 – Agreement regarding filing of joint Amendment No. 3 to Schedule 13G.
 
Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CUSIP No. G6855A 10 3
  13G Page 4 of 6 Pages 


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:       February 12, 2018
 

CLARUS LIFESCIENCES I, L.P.
 
By:    Clarus Ventures I Management, L.P., its general partner
 
By:    Clarus Ventures I, LLC, its general partner
 
By:      /s/ Robert Liptak                                      
Manager
 
CLARUS VENTURES I MANAGEMENT, L.P.
 
By:    Clarus Ventures I, LLC, its general partner
 
By:      /s/ Robert Liptak                                      
Manager
 
CLARUS VENTURES I, LLC
 
By:      /s/ Robert Liptak                                      
Manager
 
 
 
                *                                                               
Nicholas Galakatos
 
                *                                                               
Dennis Henner
 
/s/ Robert Liptak                                                   
Robert Liptak
 
                *                                                               
Nicholas Simon
 
                *                                                               
Kurt Wheeler

 
*By:        /s/ Robert Liptak                                  
Robert Liptak, as Attorney-in-Fact
 

This Amendment No. 3 to Schedule 13G was executed by Robert Liptak on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

CUSIP No. G6855A 10 3
  13G Page 5 of 6 Pages 

 
EXHIBIT 1
AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Ordinary Shares of Oxford Immunotec Global PLC.
 
Date:  February 12, 2018
 
 
CLARUS LIFESCIENCES I, L.P.
 
By:    Clarus Ventures I Management, L.P., its general partner
 
By:    Clarus Ventures I, LLC, its general partner
 
By:      /s/ Robert Liptak                                      
Manager
 
CLARUS VENTURES I MANAGEMENT, L.P.
 
By:    Clarus Ventures I, LLC, its general partner
 
By:      /s/ Robert Liptak                                      
Manager
 
CLARUS VENTURES I, LLC
 
By:      /s/ Robert Liptak                                      
Manager
 
 
 
                *                                                               
Nicholas Galakatos
 
                *                                                               
Dennis Henner
 
/s/ Robert Liptak                                                   
Robert Liptak
 
                *                                                               
Nicholas Simon
 
                *                                                               
Kurt Wheeler


*By:        /s/ Robert Liptak                                 
                Robert Liptak, as Attorney-in-Fact

This Amendment No. 3 to Schedule 13G was executed by Robert Liptak on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.
CUSIP No. G6855A 10 3
  13G Page 6 of 6 Pages 


EXHIBIT 2
 
 
POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert Liptak with full power to act singly, his true and lawful attorney-in-fact, with full power of substitution, to: (i) sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a general partner of any partnership or limited liability company, pursuant to Section 13 or 16 of the Securities Exchange Act of 1934, as amended, and any and all regulations promulgated thereunder, (ii) file the same (including any amendments thereto), with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and any stock exchange or similar authority and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this power of attorney shall be in such form and shall contain such terms and conditions as such attorney‑in‑fact may approve in such attorney‑in‑fact's discretion, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate.
 
Each of the undersigned hereby grant to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.
 
This power of attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the attorney-in-fact.
 
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 9th day of February, 2017.


/s/ Nicholas Galakatos               
Nicholas Galakatos
   

/s/ Dennis Henner                      
Dennis Henner
   

/s/ Nick Simon                              
Nick Simon
   

/s/ Scott Requadt                          
Scott Requadt
   

/s/ Kurt Wheeler                             
Kurt Wheeler